Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy.

doi:10.2174/0929867324666171003113540

Paper

Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy.

Published Jan 31, 2019 · M. Kowalik, J. Masternak, B. Barszcz

Current medicinal chemistry

Q1 SJR score

49

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

BACKGROUND Application of coordination chemistry in nanotechnology is a rapidly developing research field in medicine. Bismuth complexes have been widely used in biomedicine with satisfactory therapeutic effects, mostly in Helicobacter pylori eradication, but also as potential antimicrobial and anti-leishmanial agents. Additionally, in recent years, application of bismuth-based compounds as potent anticancer drugs has been studied extensively. METHODS Search for data connected with recent trends on bismuth compounds in cancer chemo- and radiotherapy was carried out using web-based literature searching tools such as ScienceDirect, Springer, Royal Society of Chemistry, American Chemical Society and Wiley. Pertinent literature is covered up to 2016. RESULTS In this review, based on 213 papers, we highlighted a number of current problems connected with: (i) characterization of bismuth complexes with selected thiosemicarbazone, hydrazone, and dithiocarbamate classes of ligands as potential chemotherapeutics. Literature results derived from 50 papers show that almost all bismuth compounds inhibit growth and proliferation of breast, colon, ovarian, lung, and other tumours; (ii) pioneering research on application of bismuth-based nanoparticles and nanodots for radiosensitization. Results show great promise for improvement in therapeutic efficacy of ionizing radiation in advanced radiotherapy (described in 36 papers); and (iii) research challenges in using bismuth radionuclides in targeted radioimmunotherapy, connected with choice of adequate radionuclide, targeting vector, proper bifunctional ligand and problems with 213Bi recoil daughters toxicity (derived from 92 papers). CONCLUSION This review presents recent research trends on bismuth compounds in cancer chemo- and radiotherapy, suggesting directions for future research.

Systematic Review

Study Snapshot

Bismuth compounds show promise as potential anticancer drugs, with potential for improved therapeutic efficacy in advanced radiotherapy and targeted radioimmunotherapy.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Paper

Recent Research Trends on Bismuth Compounds in Cancer Chemoand Radiotherapy.

References

Gold Nanostructures as a Platform for Combinational Therapy in Future Cancer Therapeutics

Gold nanostructures enhance tumor cell killing, drug loading, and control, leading to effective combinational therapy in cancer therapeutics.

Bismuth(III) complexes with 2-acetylpyridine- and 2-benzoylpyridine-derived hydrazones: Antimicrobial and cytotoxic activities and effects on the clonogenic survival of human solid tumor cells.

Bismuth(III) complexes with 2-acetylpyridine-derived hydrazones show more potent and selective cytotoxic effects on human solid tumor cells, potentially offering new drug candidates for colon cancer treatment.

Perfluorocarbon‐Loaded Hollow Bi2Se3 Nanoparticles for Timely Supply of Oxygen under Near‐Infrared Light to Enhance the Radiotherapy of Cancer

Hollow Bi2Se3 nanoparticles loaded with perfluorocarbon can enhance cancer radiotherapy by concentrating radiation energy in tumors and providing oxygen under near-infrared light, overcoming hypoxia-associated radio-resistance.

Quantitative 3D Determination of Radiosensitization by Bismuth-Based Nanoparticles.

Bismuth-based nanoparticles can enhance the effects of radiation in external beam radiotherapy, with potential superiority over gold nanoparticles in terms of radiation dose enhancement.

Stability and toxicity of tris-tolyl bismuth(V) dicarboxylates and their biological activity towards Leishmania major.

Tris-tolyl bismuth(V) dicarboxylates show significant toxicity towards Leishmania major promastigotes and human fibroblast cells, with o- and m-tolyl ligands showing the best activity and selectivity.

Citations

Synthesis, Crystal Structure, Formation Mechanism, Theoretical Studies, and Biological Evaluation of Azine‐Based Bismuth (III) Complex

The azine-based bismuth (III) complex shows higher antimicrobial and cytotoxic activities than free ligands, with MIC and IC50 values similar to reference drugs.

Synthesis, crystal structure, and in vitro biological evaluation of bismuth (III) complexes incorporating pyrazinohydrazide‐derived Schiff bases

Two bismuth (III) complexes incorporating Schiff bases show higher antimicrobial and cytotoxic activity than their parent ligands, with one complex showing close cytotoxic activity to Doxorubicin against SGC7901 cells.

Applications of low-valent compounds with heavy group-14 elements.

Low-valent compounds with heavy group-14 elements have significant applications in organic transformations, small molecule activation, and materials, with potential for future synthetic methodologies and applications.

Coordination environment dependence of anticancer activity in cyclometalated bismuth(III) complexes with C,O-chelating ligands.

Cyclometalate bismuth(III) complexes with C,O-chelating ligands show excellent anticancer activity and selectivity, with coordination environment-dependent cytotoxicity attributed to apoptosis.

Survey of Main Group Metals and Metalloids in Cancer Treatment

Main group metal- and metalloid-based complexes show potential as anticancer agents, offering a variety of new options for designing innovative chemopharmaceutics.